IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
April 08, 2024 07:45 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to...
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
April 05, 2024 07:45 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its...
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
March 21, 2024 07:30 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and...
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
March 14, 2024 16:30 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release...
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
March 11, 2024 07:45 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx...
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
February 20, 2024 10:50 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to...
IntelGenx Launches Preferred Share Regulation A Offering
February 20, 2024 07:50 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to...
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
February 05, 2024 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced positive results from a proof-of-concept (“POC”) study...
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
December 18, 2023 07:15 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license...
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
December 05, 2023 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced...